Onco Actu du 14 octobre 2019

	1. BIOLOGIE
An ambitious effort to map the human body’s individual cells gets backing from NIH - An ambitious effort to map the human body’s individual cells gets backing from NIH [Science] Agency to spend $200 million on comprehensive, useful, and user-friendly cell maps.
	2.7 ETIOLOGIE - OBÉSITÉ
Overweight before age 40 increases the cancer risk [University of Bergen] The risk of cancer increases considerably if you gain weight before the age of 40. For endometrial cancer, the risk increases by 70 percent.
	3.1.1 PRÉVENTION - TABAC - E-CIGS
Scientists chase cause of mysterious vaping illness as death toll rises [Nature] Confusion reins as researchers sort through the complex US e-cigarette market.
Vaping-related illness has a new name: EVALI [STAT] Health officials also pointed to a troubling observation in the outbreak: A handful of patients who were hospitalized for vaping-related illness and then discharged were later readmitted to the hospital. Those patients were hospitalized anywhere between five and 55 days after they were discharged.
No Drop in Vaping Cases, C.D.C. Says [NY Times] Health officials say the flu season may complicate diagnosis of the lung damage from vaping, masking symptoms.
U.S. health officials say vaping illness may have multiple causes [Reuters] “I think there will be multiple causes and potentially more than one root cause,” Dr. Anne Schuchat, principal deputy director of the U.S. Centers for Disease Control and Prevention (CDC), said on the call. The source of the illness in one part of the country may not be the same as in another part of the country, she said.
	4.15 DÉP., DIAG. & PRONO. - IMAGERIE
Imaging tumour stiffness could help enhance treatment for breast and pancreatic cancer [Institute of Cancer Research] Our research shows that this new type of scan can give valuable diagnostic information about breast and pancreatic tumours non-invasively by assessing their stiffness. If confirmed in a clinical trial, we could use this technique to identify patients most likely to benefit from treatments that target the dense scaffold upon which these tumours grow.
	5.17 TRAITEMENTS - RADIOTHÉRAPIE
Taking RTKI drugs during radiotherapy may not aid survival, worsens side effects [Penn State] In a meta-analysis of 11 different studies, the researchers said that treatments that included both radiotherapy and receptor tyrosine kinase inhibitor — or RTKI — drugs did not significantly improve survival rates of patients, but appeared to worsen negative side effects, such as fatigue, nausea and diarrhea.
	5.2 PHARMA
Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer [Seattle Genetics] The primary endpoint is progression-free survival per Response Evaluation Criteria in Solid Tumors (RECIST). Secondary endpoints include overall survival, objective response rate and duration of response. The trial is expected to enroll approximately 460 patients.
	5.2.3 PHARMA - ÉCONOMIE
PhRMA’s talking points shouldn’t derail the Pelosi drug pricing bill [STAT] That Roche and Novartis are dominant players and based in Switzerland exposes the false logic of this point, as drug prices are 75% lower in Switzerland than in the U.S., according to the House Ways and Means Committee. Drug prices in France, the United Kingdom, and Japan are lower, too.
	5.4 TRAITEMENTS - ECONOMIE
Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn [Fierce Pharma] With that gold-standard survival data still not available, Clovis did what almost every company has done to win over NICE: offer up a discount.
Clovis Oncology Announces Rubraca®▼ (Rucaparib) Now Available For Women With Relapsed Ovarian Cancer In England Through The Cancer Drugs Fund [Clovis Oncology] The European Union (EU) conditional marketing authorization is based on data from the pivotal Phase 3 ARIEL3 clinical trial. ARIEL3 successfully achieved its primary endpoint of extending investigator-assessed PFS versus placebo in all patients treated (intention-to-treat, or ITT), population, regardless of BRCA status (median 10.8 months vs 5.4 months).
In reversal, NICE backs Rubraca after Clovis agrees to a price cut [EndPoints] The drug was originally developed at Newcastle University, with a team involving researchers from the Northern Institute for Cancer Research and Cancer Research UK-funded scientists. It generated second-quarter sales of $33 million globally.
	6.1 OBSERVATION
Men account for a small fraction of breast cancer cases. Their fatality rate has soared compared with women’s [STAT] “Men diagnosed with breast cancer have a worse survival rate, and we don’t understand the exact reason for the disparity. We need to take a closer look at the biology and the treatment.”
Womb cancer stats reveal treatment variation across England [Cancer Research UK] But this isn’t a reflection on the doctors that treat womb cancer. Instead it brings to light a very fragmented research picture and unclear guidelines that are open to interpretation.